Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong
The University of Hong Kong
Ruijin Hospital
First Affiliated Hospital Xi'an Jiaotong University
Fox Chase Cancer Center
Stanford University
Ruijin Hospital
University of Southern California
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Washington University School of Medicine
Teva Branded Pharmaceutical Products R&D, Inc.
Northwestern University
Tehran University of Medical Sciences